DMK Pharmaceuticals Corporation Sustainability Profile
DMK Pharmaceuticals Corporation, commonly referred to as DMK, is a prominent player in the pharmaceutical industry, headquartered in the United States. Founded in 1990, the company has established itself as a leader in the development and manufacturing of innovative pharmaceutical products, particularly in the areas of dermatology and wound care. With a strong operational presence across North America and Europe, DMK Pharmaceuticals is renowned for its commitment to quality and efficacy. The company’s core offerings include advanced topical formulations and therapeutic solutions that address a variety of skin conditions, setting them apart through their unique blend of science and nature. Recognised for its dedication to research and development, DMK has achieved significant milestones, including numerous patents and awards that underscore its market position. As a trusted name in the pharmaceutical sector, DMK Pharmaceuticals continues to enhance patient care through its cutting-edge products and solutions.
DitchCarbon Score
How does DMK Pharmaceuticals Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
DMK Pharmaceuticals Corporation's score of 23 is lower than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
DMK Pharmaceuticals Corporation's reported carbon emissions
DMK Pharmaceuticals Corporation, headquartered in the US, currently does not have available carbon emissions data for the most recent year. As a result, specific figures regarding their total emissions, including Scope 1, 2, and 3, are not provided. Furthermore, there are no documented reduction targets or climate pledges from the company, indicating a lack of formal commitments to reduce carbon emissions at this time. Without emissions data or reduction initiatives, it is challenging to assess DMK Pharmaceuticals' climate impact or commitments within the pharmaceutical industry context. As the company continues to operate, it may consider establishing measurable climate goals and reporting its emissions data to align with industry standards and expectations for sustainability.
How Carbon Intensive is DMK Pharmaceuticals Corporation's Industry?
How Carbon Intensive is DMK Pharmaceuticals Corporation's Location?
DMK Pharmaceuticals Corporation's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
DMK Pharmaceuticals Corporation has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.